Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT02665650 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

BIOLOGICAL: AFM13
BIOLOGICAL: Pembrolizumab

Sponsor

Affimed GmbH

Collaborators

[object Object]
[object Object]